NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis $5.15 -0.23 (-4.28%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$5.20 +0.05 (+1.07%) As of 03/28/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cara Therapeutics Stock (NASDAQ:CARA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cara Therapeutics alerts:Sign Up Key Stats Today's Range$5.07▼$5.4350-Day Range$4.43▼$5.9952-Week Range$2.71▼$11.39Volume15,729 shsAverage Volume67,234 shsMarket Capitalization$23.56 millionP/E RatioN/ADividend YieldN/APrice Target$27.84Consensus RatingHold Company OverviewCara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More… Remove Ads Cara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreCARA MarketRank™: Cara Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 203rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has received no research coverage in the past 90 days.Read more about Cara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.93% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently increased by 13.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.39 Percentage of Shares Shorted1.93% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently increased by 13.71%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.93 News SentimentCara Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cara Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for CARA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Stock News HeadlinesCara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.comMarch 30 at 3:11 AM | americanbankingnews.comCARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARAFebruary 20, 2025 | businesswire.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 30, 2025 | Porter & Company (Ad)Europe Digital Therapeutics Market Research Report 2025-2030: Dominated by Mindable Health, Cara Care, Kaia Health Software, HealthHero, and GAIAFebruary 8, 2025 | finance.yahoo.comCara Therapeutics CEO Posner sells shares worth $1,755February 7, 2025 | msn.comCara Therapeutics CEO Christopher Posner sells $1,755 in stockFebruary 7, 2025 | msn.comCara Therapeutics regains Nasdaq complianceJanuary 18, 2025 | msn.comCARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARAJanuary 6, 2025 | businesswire.comSee More Headlines CARA Stock Analysis - Frequently Asked Questions How have CARA shares performed this year? Cara Therapeutics' stock was trading at $6.12 on January 1st, 2025. Since then, CARA shares have decreased by 15.8% and is now trading at $5.15. View the best growth stocks for 2025 here. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings data on Wednesday, August, 14th. The biopharmaceutical company reported ($4.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.24) by $1.20. The biopharmaceutical company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%. When did Cara Therapeutics' stock split? Cara Therapeutics shares reverse split on Tuesday, December 31st 2024. The 1-12 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Cara Therapeutics' major shareholders? Top institutional shareholders of Cara Therapeutics include Rockefeller Capital Management L.P. (3.41%), Farallon Capital Management LLC (2.84%), Renaissance Technologies LLC (2.06%) and Shay Capital LLC (1.88%). Insiders that own company stock include Christopher Posner, Frederique PhD Menzaghi, Scott Terrillion, Joana Goncalves, Martin Vogelbaum, Jeffrey L Ives and Ryan D Maynard. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA). Company Calendar Last Earnings8/14/2024Today3/30/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARA CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$27.84 High Stock Price Target$60.00 Low Stock Price Target$12.00 Potential Upside/Downside+440.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($21.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-1,099.76% Pretax Margin-1,099.76% Return on Equity-367.97% Return on Assets-107.43% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.71 Sales & Book Value Annual Sales$7.14 million Price / Sales3.30 Cash FlowN/A Price / Cash FlowN/A Book Value$12.58 per share Price / Book0.41Miscellaneous Outstanding Shares4,574,000Free Float4,429,000Market Cap$23.56 million OptionableOptionable Beta0.50 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CARA) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.